Clene, Inc. (CLNN)
3.85
-0.14
(-3.63%)
USD |
NASDAQ |
Sep 04, 16:00
3.85
0.00 (0.00%)
After-Hours: 20:00
Clene Research and Development Expense (Quarterly) : 3.135M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.135M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 5.164M |
| September 30, 2025 | 3.176M |
| June 30, 2025 | 3.177M |
| March 31, 2025 | 1.143M |
| December 31, 2024 | 5.229M |
| September 30, 2024 | 4.132M |
| June 30, 2024 | 3.803M |
| March 31, 2024 | 5.515M |
| December 31, 2023 | 6.318M |
| September 30, 2023 | 5.599M |
| June 30, 2023 | 6.24M |
| Date | Value |
|---|---|
| March 31, 2023 | 7.06M |
| December 31, 2022 | 7.533M |
| September 30, 2022 | 6.237M |
| June 30, 2022 | 8.946M |
| March 31, 2022 | 8.38M |
| December 31, 2021 | 9.251M |
| September 30, 2021 | 5.946M |
| June 30, 2021 | 6.272M |
| March 31, 2021 | 6.075M |
| December 31, 2020 | 4.154M |
| September 30, 2020 | 3.794M |
| June 30, 2020 | 3.354M |
| March 31, 2020 | 3.002M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 0.917M |
| Summit Therapeutics, Inc. | 157.73M |
| Kezar Life Sciences, Inc. | 1.545M |
| Protara Therapeutics, Inc. | 16.88M |